Tags

Type your tag names separated by a space and hit enter

The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic.
Vaccine. 2011 Feb 17; 29(9):1777-82.V

Abstract

We evaluated the formation of hemagglutination-inhibition (HI) antibodies in response to vaccination of 55 allogeneic and 23 autologous hematopoietic stem cell transplantation (HSCT) recipients with 3.75 μg inactivated influenza A/California/7/2009 (H1N1)v-like virus adjuvanted with AS03, given towards the end of the 2009 influenza pandemic. The 78 HSCT recipients, aged 11-72 (median 50) years, were vaccinated 1-290 (median 27) months post-HSCT. Of the 55 allogeneic HSCT recipients, 50.9% received reduced intensity conditioning, 74.5% had a sibling donor, 67.2% had active graft-versus-host disease and 43.6% were on steroid therapy. At baseline, 14/78 (17.9%) had HI titers ≥ 1:40. Blood samples of 77 patients were available post-1st vaccination; of these, 34 (44.2%) patients had HI titers ≥ 1:40. Blood samples of 43 patients were available post-2nd vaccination; of these, 21 (48.8%) had HI titers ≥ 1:40. There was a significant increase in HI titers ≥ 1:40 from baseline to both post-1st and 2nd vaccinations (p<0.001 each), and also from 1st to 2nd vaccination (p=0.008). In seronegative (HI titers <1:10) patients, whose sera were available before, after one dose, and after 2 doses of vaccine, seroconversion (to ≥ 1:40) occurred in 4/24 (16.7%) after 1-dose and in a total of 10/24 (41.7%) after 2-dose vaccination (p=0.031). Logistic regression analysis revealed that ≥ 1:40 HI titers were significantly associated with higher lymphocyte counts and higher HI baseline titers and, in allogeneic HSCT, with having a sibling donor and higher baseline titers. In conclusion, 2-dose vaccination with AS03-adjuvanted vaccine containing 3.75 μg antigen resulted in a statistically significant, yet limited, serological response. Therefore, additional precautions should be taken during influenza outbreaks.

Authors+Show Affiliations

Department of Pediatrics, Hadassah University Hospital, Ein Kerem, Jerusalem, Israel. engelhard@hadassah.org.ilNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21216315

Citation

Engelhard, Dan, et al. "The Humoral Immune Response of Hematopoietic Stem Cell Transplantation Recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like Virus Vaccine During the 2009 Pandemic." Vaccine, vol. 29, no. 9, 2011, pp. 1777-82.
Engelhard D, Zakay-Rones Z, Shapira MY, et al. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine. 2011;29(9):1777-82.
Engelhard, D., Zakay-Rones, Z., Shapira, M. Y., Resnick, I., Averbuch, D., Grisariu, S., Dray, L., Djian, E., Strauss-Liviatan, N., Grotto, I., Wolf, D. G., & Or, R. (2011). The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine, 29(9), 1777-82. https://doi.org/10.1016/j.vaccine.2010.12.113
Engelhard D, et al. The Humoral Immune Response of Hematopoietic Stem Cell Transplantation Recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like Virus Vaccine During the 2009 Pandemic. Vaccine. 2011 Feb 17;29(9):1777-82. PubMed PMID: 21216315.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. AU - Engelhard,Dan, AU - Zakay-Rones,Zichria, AU - Shapira,Michael Y, AU - Resnick,Igor, AU - Averbuch,Diana, AU - Grisariu,Sigal, AU - Dray,Lillian, AU - Djian,Esther, AU - Strauss-Liviatan,Nurith, AU - Grotto,Itamar, AU - Wolf,Dana G, AU - Or,Reuven, Y1 - 2011/01/07/ PY - 2010/11/02/received PY - 2010/12/21/revised PY - 2010/12/22/accepted PY - 2011/1/11/entrez PY - 2011/1/11/pubmed PY - 2011/6/18/medline SP - 1777 EP - 82 JF - Vaccine JO - Vaccine VL - 29 IS - 9 N2 - We evaluated the formation of hemagglutination-inhibition (HI) antibodies in response to vaccination of 55 allogeneic and 23 autologous hematopoietic stem cell transplantation (HSCT) recipients with 3.75 μg inactivated influenza A/California/7/2009 (H1N1)v-like virus adjuvanted with AS03, given towards the end of the 2009 influenza pandemic. The 78 HSCT recipients, aged 11-72 (median 50) years, were vaccinated 1-290 (median 27) months post-HSCT. Of the 55 allogeneic HSCT recipients, 50.9% received reduced intensity conditioning, 74.5% had a sibling donor, 67.2% had active graft-versus-host disease and 43.6% were on steroid therapy. At baseline, 14/78 (17.9%) had HI titers ≥ 1:40. Blood samples of 77 patients were available post-1st vaccination; of these, 34 (44.2%) patients had HI titers ≥ 1:40. Blood samples of 43 patients were available post-2nd vaccination; of these, 21 (48.8%) had HI titers ≥ 1:40. There was a significant increase in HI titers ≥ 1:40 from baseline to both post-1st and 2nd vaccinations (p<0.001 each), and also from 1st to 2nd vaccination (p=0.008). In seronegative (HI titers <1:10) patients, whose sera were available before, after one dose, and after 2 doses of vaccine, seroconversion (to ≥ 1:40) occurred in 4/24 (16.7%) after 1-dose and in a total of 10/24 (41.7%) after 2-dose vaccination (p=0.031). Logistic regression analysis revealed that ≥ 1:40 HI titers were significantly associated with higher lymphocyte counts and higher HI baseline titers and, in allogeneic HSCT, with having a sibling donor and higher baseline titers. In conclusion, 2-dose vaccination with AS03-adjuvanted vaccine containing 3.75 μg antigen resulted in a statistically significant, yet limited, serological response. Therefore, additional precautions should be taken during influenza outbreaks. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/21216315/The_humoral_immune_response_of_hematopoietic_stem_cell_transplantation_recipients_to_AS03_adjuvanted_A/California/7/2009__H1N1_v_like_virus_vaccine_during_the_2009_pandemic_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(10)01900-6 DB - PRIME DP - Unbound Medicine ER -